Drug Development Drug Pricing Webinar 
Safe Biologics
JULY 13, 2023
On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines which focused on unintended consequences for patient access that may result from the implementation of the Inflation Reduction Act (IRA).
Safe Biologics
SEPTEMBER 12, 2023
ASBM & GaBI Webinar on Medicare Price Negotiation Examines Impact on Innovation, Patient Access On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Safe Biologics
JULY 20, 2023
REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.
Safe Biologics
JULY 20, 2023
REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.
Pharma Marketing Network
MARCH 13, 2025
However, growing concerns about drug pricing, misleading claims, and overprescription have led policymakers to consider banning pharma ads from television altogether. Email marketing campaigns can keep healthcare professionals informed about drug developments. Why is a pharma ad ban on TV being considered?
Safe Biologics
NOVEMBER 12, 2023
View the full webinar here or watch individual segments linked below. Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J. Thanks to the IRA’s price controls, medical marvels like Keytruda will now be even more difficult to achieve.
Big Molecule Watch
SEPTEMBER 14, 2023
Two weeks ago, HHS announced the first 10 drugs that will be subject to the new Drug Price Negotiation Program under the Inflation Reduction Act (“IRA”). Six of the manufacturers whose drugs are on the list and several other interested groups have filed lawsuits challenging the Program.
Expert insights. Personalized for you.
130 
Let's personalize your content